Catheter Lock Solution presentation
Citra-Lock™
Unternehmensprofil
Video
Broschüre
Information & Publikationen
F.A.Q.
Links
Anmelden
Newsletter
Kontakt
Home
| Information & Publikationen
Wissenschaftliche Information & Publikationen
Anfrage von
Bitte geben Sie ihre Kontaktdaten ein und überprüfen Sie die erwünschten Informationen. Wir werden Ihnen die Artikel im Volltext zuschicken:
Vorname: *
Nachname: *
Berufsbezeichnung:
Unternehmen: *
Abteilung: *
Land: *
Bitte auswählen...
none
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegowina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Cote d'Ivoire
Croatia (Hrvatska)
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
France, Metropolitan
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Heard and Mc Donald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran (Islamic Republic of)
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia, The Former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Kitts and Nevis
Saint LUCIA
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia (Slovak Republic)
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
St. Helena
St. Pierre and Miquelon
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands (British)
Virgin Islands (U.S.)
Wallis and Futuna Islands
Western Sahara
Yemen
Yugoslavia
Zambia
Zimbabwe
Nicht aufgelistet
Stadt: *
Emailadresse: *
Kommentare:
Citra-Flow 4% & Citra-Lock 4% :
1. Bayes B et al (1999) Sodium Citrate for filling hemodiaysis catheters. Nephrol Dial Transplant 14, 2532-2533
2. Buturovic J et al (1998) Filling hemodialysis catheters in the interdialytic period. Artif Organs 22, 945-947
3. Grudzinski L et al (2007) Sodium citrate 4% locking solution for central venous dialysis catheters-an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 22: 471-476
4. Hendrickx L et al (2001) A comparative study on the use of low concentrate citrate lock. Int J Artif Organs 24, 208-211
5. Lok CE et al (2005) Trisodium citrate 4%-an alternatieve to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 22, 477-483
6. Meeus G et al (2005) A prospective, randomized, double-blind crossover study on the use of 5% citrate-lock vs 10% citrate-lock. Blood Purif 23, 101-105
7. Michaud D et al (2001) Four percent trisodium citrate as an effective anticoagulant. Am J Crit Care 10, 351-354
8. Moran JE and Ash SE (2008) Locking Solutions for Hemodialysis Catheters; Heparin and Citrate. A Position Paper by ASDIN. Seminars in Dialysis 21,1-3
9. Dreyer G et al (2008) Heparin leak from a hemodialysis catheter causing major bleeding, ultimately leading to transplant rejection and death. HDI Volume 12, Number 4, October 2008, pp. 431-433(3)
Alle auswählen
Citra-Lock 30% & Citra-Lock 46,7% :
1. Ash SR (2000) Concentrated Sodium Citrate (23%) for Catheter Lock. Haemodialysis International 4:22-31
2. Weijmer JC (2005) Randomized, Clinical Trial Comparison of Trisodium Citrate 30% and Heparin as Catheter-Locking Solution in Haemodialysis Patients. J Am Soc Nephrol. Sep;16(9):2769-77
3. Weijmer JC (2002) Superior Antimicrobial Activity of Trisodium Citrate over Heparin for Catheter Locking. Nephrol Dial Transplant 17: 2189-2195
4. Shanks RM (2006) Catheter Lock Solutions Influence Staphylococcal Biofilm Formation on Abiotic Surfaces. Nephrol Dial Transplant 21, 2247-2255
5. Nolan JP (2007) Reducing Catheter Related Bacteraemia in Haemodialysis. Vascular Access Soc. 5th Int. Congress of Vascular Access Soc, Nice
6. VU Amsterdam(2005), Agar diffusion susceptibility test for heparine, Cita-Lock30% en Citra-Lock 46,7%, Microbiological lab VU Amsterdam
7. Organs (1998) Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study, 1998 Nov;22(11):945-7
8. Hendrikx L (2001) A comparative prospective study on the use of low concentrate citrate lock versus heparine lock in permanent dialysis catheters. Int J Artif Organs 2001 Apr; 24(4):208-11
9. Donlan RM (2001) Biofilms and Device-Associated Infections. Emerging Infectious Diseases, Vol. 7, No. 2, March-April 2001
10. Karaaslan H (2001) Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Neprol Dial Transplant (2001) 16: 2072-2074
11. Nielsen J (1998) Staphylococcus aureus bacteraemia among patients undergoing dialysis-focus on dialysis catheter-related cases. Nephrol Dial Transplant (1998) 13: 139-145
12. Jean G (2002) Risk factor analysis for long-term tunneled dialysis catheterrelated bacteremias. Nephron 2002 Jul;91(3):399-405
13. Jeffrey S. Berns JS (2002) Preventing Bacterial Infections and Antimicrobial Resistance in Dialysis Patients. American Journal of Kidney Diseases, Vol 40, No 5 (November), 2002:pp 886-898
14. Peleman RA (2000) Changing patterns of antibiotic resistance- update on antibiotic management of the infected vascular access. Neprol Dial Transplant (2000) 15: 1281-1284
15. Betjes MGH (2004) Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant (2004) 19: 1546-1551
16. Doorenbos CJ (2005) Estimation of trisodium citrate (Citra-LockTM) remaining in central venous catheters after the interdialytic interval. Nephrol Dial Transplant (2005) 1 of 3, doi:10.1093/ndt/gfi331
17. Agharazii M (2005) Estimation of heparin leak into the systemic circulation after central venous catheter heparin lock. Nephrol Dial Transplant (2005) 20: 1238-1240, doi:10.1093/ndt/gfh841
18. Srivastava R (2004) The case of the floating gel. J Clin Pathol 2004;57:1333-1334. doi: 10.1136/jcp.2004.020495
Alle auswählen
* Erforderliche Felder